These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 6125455)

  • 1. Update on antiparkinsonian agents.
    Weiner M
    Geriatrics; 1982 Sep; 37(9):81-4, 89-91. PubMed ID: 6125455
    [No Abstract]   [Full Text] [Related]  

  • 2. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinson's disease in the elderly: current management strategies.
    Aminoff MJ
    Geriatrics; 1987 Jul; 42(7):31-7. PubMed ID: 3110015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ; Metman LV; Chase TN
    Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
    [No Abstract]   [Full Text] [Related]  

  • 5. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amantadine-induced "vocal" myoclonus.
    Pfeiffer RF
    Mov Disord; 1996 Jan; 11(1):104-6. PubMed ID: 8771080
    [No Abstract]   [Full Text] [Related]  

  • 7. [Stage-adjusted treatment of idiopathic Parkinson syndrome].
    Ludin HP
    Wien Med Wochenschr; 1995; 145(13):294-8. PubMed ID: 7571654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions.
    Harvey NS
    Psychosomatics; 1986 Mar; 27(3):175-7, 180, 181-4. PubMed ID: 2870536
    [No Abstract]   [Full Text] [Related]  

  • 9. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
    Furukawa Y; Filiano JJ; Kish SJ
    Mov Disord; 2004 Oct; 19(10):1256-8. PubMed ID: 15389992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current treatment of the Parkinsonian syndrome].
    Voiculescu V
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1985; 30(3):161-6. PubMed ID: 2868512
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drugs and indications for medical treatment in Parkinson's disease (author's transl)].
    Allain H; Van den Driessche J; Menault F; Pape D; Reymann JM; Bentue-Ferrer D
    Sem Hop; 1980 Feb 8-15; 56(5-6):277-82. PubMed ID: 6243802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs for parkinsonism.
    Med Lett Drugs Ther; 1986 Jun; 28(716):62-4. PubMed ID: 3713639
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion.
    van Laar T; Lammers GJ; Roos RA; Gerritsen JJ; Meinders AE
    Mov Disord; 1998 Jan; 13(1):176-8. PubMed ID: 9452348
    [No Abstract]   [Full Text] [Related]  

  • 19. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of L-dopa induced dyskinesia and of on-off phenomenon by bromocriptine.
    Ludin HP
    Acta Neurol Belg; 1980; 80(1):5-9. PubMed ID: 7361542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.